Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

A guide to cancer immunotherapy: from T cell basic science to clinical practice
Alex D. Waldman, Jill M. Fritz, Michael J. Lenardo
Nature reviews. Immunology (2020) Vol. 20, Iss. 11, pp. 651-668
Open Access | Times Cited: 3194

Showing 1-25 of 3194 citing articles:

Therapeutic Targeting of the Tumor Microenvironment
Leire Bejarano, Marta Joana Costa Jordão, Johanna A. Joyce
Cancer Discovery (2021) Vol. 11, Iss. 4, pp. 933-959
Open Access | Times Cited: 1062
Antigen presentation in cancer: insights into tumour immunogenicity and immune evasion
Suchit Jhunjhunwala, Christian Hammer, Lélia Delamarre
Nature reviews. Cancer (2021) Vol. 21, Iss. 5, pp. 298-312
Closed Access | Times Cited: 968
Clinical and therapeutic relevance of cancer-associated fibroblasts
Yang Chen, Kathleen M. McAndrews, Raghu Kalluri
Nature Reviews Clinical Oncology (2021) Vol. 18, Iss. 12, pp. 792-804
Open Access | Times Cited: 750
Attacking the PI3K/Akt/mTOR signaling pathway for targeted therapeutic treatment in human cancer
Le Yu, Jessica Wei, Pengda Liu
Seminars in Cancer Biology (2021) Vol. 85, pp. 69-94
Closed Access | Times Cited: 381
Annual Report to the Nation on the Status of Cancer, Part 1: National Cancer Statistics
Farhad Islami, Elizabeth Ward, Hyuna Sung, et al.
JNCI Journal of the National Cancer Institute (2021) Vol. 113, Iss. 12, pp. 1648-1669
Open Access | Times Cited: 379
Metastasis
Stefanie Gerstberger, Qingwen Jiang, Karuna Ganesh
Cell (2023) Vol. 186, Iss. 8, pp. 1564-1579
Open Access | Times Cited: 354
Diffuse Glioma Heterogeneity and Its Therapeutic Implications
James Nicholson, Howard A. Fine
Cancer Discovery (2021) Vol. 11, Iss. 3, pp. 575-590
Open Access | Times Cited: 313
CD8+ T Cell Exhaustion in Cancer
Joseph S. Dolina, Natalija Budimir, Graham D. Thomas, et al.
Frontiers in Immunology (2021) Vol. 12
Open Access | Times Cited: 309
The cGAS–STING pathway and cancer
Natasha Samson, Andrea Ablasser
Nature Cancer (2022) Vol. 3, Iss. 12, pp. 1452-1463
Closed Access | Times Cited: 291
Modes of Regulated Cell Death in Cancer
Elle Koren, Yaron Fuchs
Cancer Discovery (2021) Vol. 11, Iss. 2, pp. 245-265
Open Access | Times Cited: 285
Nanomedicine in cancer therapy
Dahua Fan, Yongkai Cao, Meiqun Cao, et al.
Signal Transduction and Targeted Therapy (2023) Vol. 8, Iss. 1
Open Access | Times Cited: 282
Tumor‐Microenvironment‐Responsive Nanomedicine for Enhanced Cancer Immunotherapy
Shaojun Peng, Fengfeng Xiao, Meiwan Chen, et al.
Advanced Science (2021) Vol. 9, Iss. 1
Open Access | Times Cited: 278
Intratumoral plasma cells predict outcomes to PD-L1 blockade in non-small cell lung cancer
Namrata S. Patil, Barzin Y. Nabet, Sören Müller, et al.
Cancer Cell (2022) Vol. 40, Iss. 3, pp. 289-300.e4
Open Access | Times Cited: 269
The Evasion Mechanisms of Cancer Immunity and Drug Intervention in the Tumor Microenvironment
Seong Keun Kim, Sun Wook Cho
Frontiers in Pharmacology (2022) Vol. 13
Open Access | Times Cited: 259
COVID-19 and Cancer: Current Challenges and Perspectives
Ziad Bakouny, Jessica E. Hawley, Toni K. Choueiri, et al.
Cancer Cell (2020) Vol. 38, Iss. 5, pp. 629-646
Open Access | Times Cited: 257
Therapeutic strategies targeting inflammation and immunity in atherosclerosis: how to proceed?
Suzanne E. Engelen, Alice Robinson, Yasemin-Xiomara Zurke, et al.
Nature Reviews Cardiology (2022) Vol. 19, Iss. 8, pp. 522-542
Open Access | Times Cited: 255
Current applications and future perspective of CRISPR/Cas9 gene editing in cancer
Siwei Wang, Chao Gao, Yi-Min Zheng, et al.
Molecular Cancer (2022) Vol. 21, Iss. 1
Open Access | Times Cited: 254
Molecular targeted therapy for anticancer treatment
Hye‐Young Min, Ho‐Young Lee
Experimental & Molecular Medicine (2022) Vol. 54, Iss. 10, pp. 1670-1694
Open Access | Times Cited: 247
Tumor Immune Microenvironment during Epithelial–Mesenchymal Transition
Mana Taki, Kaoru Abiko, Masayo Ukita, et al.
Clinical Cancer Research (2021) Vol. 27, Iss. 17, pp. 4669-4679
Open Access | Times Cited: 234
Immunobiology and immunotherapy of HCC: spotlight on innate and innate-like immune cells
Benjamin Ruf, Bernd Heinrich, Tim F. Greten
Cellular and Molecular Immunology (2020) Vol. 18, Iss. 1, pp. 112-127
Open Access | Times Cited: 233
Neoantigen: A New Breakthrough in Tumor Immunotherapy
Zheying Zhang, Manman Lu, Yu Qin, et al.
Frontiers in Immunology (2021) Vol. 12
Open Access | Times Cited: 217
Tumor microenvironment: barrier or opportunity towards effective cancer therapy
Aadhya Tiwari, Rakesh Trivedi, Shiaw‐Yih Lin
Journal of Biomedical Science (2022) Vol. 29, Iss. 1
Open Access | Times Cited: 207
Signaling Pathways in Cancer: Therapeutic Targets, Combinatorial Treatments, and New Developments
Hon Yan Kelvin Yip, Antonella Papa
Cells (2021) Vol. 10, Iss. 3, pp. 659-659
Open Access | Times Cited: 203
Augmenting Anticancer Immunity Through Combined Targeting of Angiogenic and PD-1/PD-L1 Pathways: Challenges and Opportunities
Stephen P. Hack, Andrew X. Zhu, Yulei Wang
Frontiers in Immunology (2020) Vol. 11
Open Access | Times Cited: 201
The chemistry and applications of hafnium and cerium(iv) metal–organic frameworks
Zhigang Hu, Yuxiang Wang, Dan Zhao
Chemical Society Reviews (2021) Vol. 50, Iss. 7, pp. 4629-4683
Closed Access | Times Cited: 186
Page 1 - Next Page

Scroll to top